Delivery Order SPE2DB20D1047-SPE2DB24FF89D

Award Date 9/23/24
Potential Completion Date 9/24/24
Potential Value $9.4K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $10,760.70, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a medical product. The contract is a Delivery Order with a Firm Fixed Price pricing type, and the ultimate completion date is December 24, 2024. The contract was awarded on December 23, 2024 and does not have a set-aside...
This federal contract award, with an ID of SPE2DB22D3016|SPE2DB25FANN1, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $10,334.40, is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract is a Firm Fixed Price Delivery Order, with a completion date of February 19, 2025. The contract does not have a set-aside designation, indicating...
This federal contract award is a delivery order valued at $2,540.23, issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a completion date of February 9, 2024. The contract type is firm fixed price. Amerisourcebergen Drug Corp is an established prime contractor providing a wide range of pharmaceutical products and medical supplies...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $8,428.28, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a firm fixed-price pricing type and an ultimate completion date of August 21, 2024. This order is not designated as a set-aside contract. Amerisourcebergen Drug Corp, through its Corporate Office division, has been awarded...
This federal contract award, valued at $12,596.20, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of PULMOZYME 1 MG/ML AMPUL 2.5ML, a critical medical product, with a completion date of May 6, 2022. This is a delivery order contract with a firm fixed price pricing type. Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc., is a key vendor for federal healthcare...
The federal contract award, identified as SPE2DX15D1053|SPE2DX25F6CYL, was granted to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,127.11 delivery order contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of November 7, 2024. The contract is not...
This federal contract award, valued at $20,646.00, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order to supply PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The award is not associated with a set-aside program and is a firm fixed-price contract scheduled for completion by December 20, 2024. Amerisourcebergen Drug Corp holds a significant Indefinite...
This federal contract award, valued at $30,965.01, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a firm-fixed-price delivery order for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a specialty pharmaceutical product. The contract has an ultimate completion date of May 22, 2024. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
The U.S. Defense Logistics Agency (DLA) Troop Support Medical has awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to supply PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. The contract has a potential value of $2,410.99 and a completion date of February 12, 2024. Amerisourcebergen Drug Corp is the prime contractor, and no set-aside designation was used for this award. Amerisourcebergen Drug Corp also holds...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,096.22, is for the supply of PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product, with a period of performance through January 29, 2025. The contract has a firm fixed price pricing type and does not have a set-aside designation, indicating open competition. AmerisourceBergen...
  • SPE2DB20D1047
    Indefinite Delivery Contract
  • SPE2DB20D1047-SPE2DB24FF89D
    Delivery Order

This federal contract award, valued at $9,411.56, was issued by the Defense Logistics Agency (DLA) to the prime contractor Amerisourcebergen Drug Corp, Corporate Office Division. The contract is for the delivery of 4565902500 - PULMOZYME 1 MG/ML AMPUL 2.5ML, a pharmaceutical product. It is a delivery order contract with a firm fixed price pricing type. The contract has an ultimate completion date of September 24, 2024. Amerisourcebergen, a major supplier of pharmaceutical products and medical supplies to the U.S. government, has been awarded numerous federal contracts by various defense and civilian agencies, including the DLA Troop Support Medical. The company holds several Indefinite Delivery Contracts (IDCs) that serve as primary vehicles for providing a comprehensive range of medical commodities to support military treatment programs and other federal healthcare needs.

Generated 12/23/24, 2:36 PM